Effects of 12-O-Tetradecanoylphorbol-13-acetate on Estrogen Receptor Activity in MCF-7 Cells (∗)

• Published in: The Journal of biological chemistry Vol. 270; no. 42; pp. 25244 - 25251
• Main Authors: Martin, Mary Beth, Garcia-Morales, Pilar, Stoica, Adriana, Solomon, Harrison B., Pierce, Meredith, Katz, Deborah, Zhang, Shimin, Danielsen, Mark, Saceda, Miguel
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 20.10.1995; American Society for Biochemistry and Molecular Biology
• Subjects: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Base Sequence; Breast Neoplasms - chemistry; Dose-Response Relationship, Drug; Estradiol - metabolism; Female; Humans; Isoquinolines - pharmacology; Molecular Sequence Data; Piperazines - pharmacology; Protein Kinase C - physiology; Receptors, Estrogen - analysis; Receptors, Estrogen - drug effects; Receptors, Estrogen - physiology; Receptors, Glucocorticoid - drug effects; Tetradecanoylphorbol Acetate - pharmacology; Tumor Cells, Cultured
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.270.42.25244

The effects of long term treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) on estrogen receptor (ER) expression in the human breast cancer cell line, MCF-7, were studied. This study demonstrates that treatment of cells with the phorbol ester blocked estrogen receptor activity. Treatment of cells with 100 nM TPA resulted in an 80% decrease in the level of ER protein and a parallel decrease in ER mRNA and binding capacity. Following removal of TPA from the medium, the level of ER protein and mRNA returned to control values; however, the receptor failed to bind estradiol. These cells also failed to induce progesterone receptor in response to estradiol. In addition, TPA treatment blocked transcription from an estrogen response element in transient transfection assays and inhibited ER binding to its response element in a DNA mobility shift assay. The estrogen receptor in treated cells was recognized by two monoclonal anti-ER antibodies and was not quantitatively different from ER in control cells. RNase protection analysis failed to detect any qualitative changes in the ER mRNA transcript. Mixing experiments suggest that TPA induces/activates a factor which interacts with the ER to block binding of estradiol. The effects of TPA on ER levels and binding capacity were concentration-dependent. Low concentrations of TPA inhibited estradiol binding without a decrease in the level of protein, whereas higher concentrations were required to decrease the level of ER protein. The effects of TPA appear to be mediated by activation of protein kinase C since the protein kinase C inhibitors, H-7 and bryostatin, block the effects of TPA on estradiol induction of progesterone receptor. TPA treatment had no effect on the level or binding capacity of the glucocorticoid receptor, indicating that the effects are not universal for steroid receptors. These data demonstrate that activation of the protein kinase C signal transduction pathway modulates the estrogen receptor pathway. The long term effect of protein kinase C activation is to inhibit estrogen receptor function through induction/activation of a factor which interacts with the receptor.